Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

September 24, 2009 updated by: Wyeth is now a wholly owned subsidiary of Pfizer

Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.

The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

180

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Antequera (Málaga), Spain
      • Avila, Spain
      • Barcelona, Spain
      • Berga (Barcelona), Spain
      • Caceres, Spain
      • Castellón, Spain
      • Ciudad Real, Spain
      • Cuenca, Spain
      • Cádiz, Spain
      • Ferrol, Spain
      • Granada, Spain
      • Jaen, Spain
      • Las Palmas, Spain
      • Lorca (Murcia), Spain
      • Lugo, Spain
      • Lérida, Spain
      • Madrid, Spain
      • Osuna (Sevilla), Spain
      • Palma Mallorca, Spain
      • Pamplona, Spain
      • Pontevedra, Spain
      • Terrasa, Spain
      • Torrelavega, Spain
      • Valencia, Spain
      • Valladolid, Spain
      • Vitoria, Spain
      • Zaragoza, Spain

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients treated at internal medicine units

Description

Inclusion Criteria:

  • Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.

Exclusion Criteria:

  • Patients known, or thought to be hypersensitivity to beta-lactams
  • Patients with an uncomplicated urinary tract infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2004

Primary Completion (Actual)

July 1, 2007

Study Completion (Actual)

July 1, 2007

Study Registration Dates

First Submitted

September 12, 2005

First Submitted That Met QC Criteria

September 12, 2005

First Posted (Estimate)

September 19, 2005

Study Record Updates

Last Update Posted (Estimate)

September 25, 2009

Last Update Submitted That Met QC Criteria

September 24, 2009

Last Verified

September 1, 2009

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 101315

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urinary Infections

Clinical Trials on piperacillin/tazobactam

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe